[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Nervgen Pharma Corp (NGEN)

Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 183,839
  • Shares Outstanding, K 80,631
  • Annual Sales, $ 0 K
  • Annual Income, $ -31,570 K
  • EBIT $ -23 M
  • EBITDA $ -23 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 15.09

Options Overview Details

View History
  • Implied Volatility 627.59% (+61.99%)
  • Historical Volatility 43.64%
  • IV Percentile 79%
  • IV Rank 48.40%
  • IV High 1,276.91% on 06/05/26
  • IV Low 18.59% on 02/17/26
  • Expected Move (DTE 18) 0.17 (7.56%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 46
  • Volume Avg (30-Day) 156
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 7,958
  • Open Int (30-Day) 7,408
  • Expected Range 2.08 to 2.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.06
  • Number of Estimates 3
  • High Estimate $0.01
  • Low Estimate $-0.11
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.61 +40.81%
on 08/03/26
2.40 -5.83%
on 08/28/26
+0.64 (+39.51%)
since 07/31/26
3-Month
1.58 +43.04%
on 07/29/26
2.40 -5.83%
on 08/28/26
+0.19 (+9.18%)
since 05/29/26
52-Week
1.58 +43.04%
on 07/29/26
6.30 -64.13%
on 01/08/26
-0.44 (-16.27%)
since 08/28/25

Most Recent Stories

More News
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal...

NGEN : 2.25 (-1.54%)
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

Site activation and screening for the Phase 3 RESTORE study is expected to begin in September 2026, with the first participant anticipated to be dosed shortly thereafter.  Strengthened leadership team,...

NGEN : 2.25 (-1.54%)
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NVG-291 demonstrated statistically significant improvement in gait quality (p=0.0197), based on a Global Statistical Test integrating the established...

NGEN : 2.25 (-1.54%)
NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study

NVG-291 demonstrated statistically significant improvement in gait quality (p=0.0197), based on a Global Statistical Test integrating the established hallmarks of genuine neural recovery into a unified...

NGEN : 2.25 (-1.54%)
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class...

NGEN : 2.25 (-1.54%)
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities

VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company

NGEN : 2.25 (-1.54%)
NervGen Announces Proposed Public Offering of Securities

The Base Shelf Prospectus is, and the Prospectus Supplement will be accessible within two business days, through SEDAR+ VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma...

NGEN : 2.25 (-1.54%)
NervGen Announces Proposed Public Offering of Securities

The Base Shelf Prospectus is, and the Prospectus Supplement will be accessible within two business days, through SEDAR+ VANCOUVER, British Columbia, May ...

NGEN : 2.25 (-1.54%)
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

Completed successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a registrational study of NVG-291 in chronic...

NGEN : 2.25 (-1.54%)
NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates

Completed successful FDA End-of-Phase 2 meeting, reaching alignment on the study parameters of RESTORE, a registrational study of NVG-291 in chronic tetraplegia, with site activation underway and study...

NGEN : 2.25 (-1.54%)

Business Summary

NervGen Pharma Corp. is a clinical-stage biopharmaceutical company developing neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions. NervGen Pharma Corp. is based in VANCOUVER, British Columbia.

See More

Key Turning Points

3rd Resistance Point 2.53
2nd Resistance Point 2.46
1st Resistance Point 2.37
Last Price 2.25
1st Support Level 2.22
2nd Support Level 2.15
3rd Support Level 2.06

See More

52-Week High 6.30
Fibonacci 61.8% 4.50
Fibonacci 50% 3.94
Fibonacci 38.2% 3.38
Last Price 2.25
52-Week Low 1.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.